February 14,
2019
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
February 12,
2019
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update
February 4,
2019
Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors